BBNX vs CYTK: fair value comparison
Beta Bionics, Inc. and Cytokinetics, Incorporated · Updated 2026-10-19
BBNX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. CYTK has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, BBNX currently ranks higher by quality score.
| BBNX | CYTK | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $16.35 | $61.95 |
| 12-month range | $8.86–$31.99 | $57.50–$87.26 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #96 of 301 Healthcare | #98 of 301 Healthcare |
| Quality grade | C | C |
| Leverage | Low | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | High | — |
| RSI zone | Oversold | Neutral |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The lower-middle quarter | The bottom quarter |
Full single-stock breakdowns: BBNX fair value analysis · CYTK fair value analysis